Fruchart J.-C.Santos R.D.Aguilar-Salinas C.Aikawa M.Al Rasadi K.Amarenco P.Barter P.J.Ceska R.Corsini A.Despr?s J.-P.Duriez P.Eckel R.H.Ezhov M.V.Farnier M.Ginsberg H.N.Hermans M.P.Ishibashi S.Karpe F.Kodama T.Koenig W.Krempf M.Lim S.Lorenzatti A.J.McPherson R.Nu?ez-Cortes J.M.Nordestgaard B?.G.Ogawa H.Packard C.J.Plutzky J.Ponte-Negretti C.I.Pradhan A.Ray K.K.Reiner Z.Ridker P.M.Ruscica M.Sadikot S.Shimano H.Sritara P.Stock J.K.TA-CHEN SUSusekov A.V.Tartar A.Taskinen M.-R.Tenenbaum A.Tokg?zo?lu L.S.Tomlinson B.Tybj?rg-Hansen A.Valensi P.Vrabl?k M.Wahli W.Watts G.F.Yamashita S.Yokote K.Zambon A.Libby P.2020-09-282020-09-2820191475-2840https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066822428&doi=10.1186%2fs12933-019-0864-7&partnerID=40&md5=86ea08c85ae32a4eaefffc68f64c90a1https://scholars.lib.ntu.edu.tw/handle/123456789/514735In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARMα agonist and concluded that this agent represents a novel therapeutic class, distinct from fibrates, based on pharmacological activity, and, importantly, a safe hepatic and renal profile. The ongoing PROMINENT cardiovascular outcomes trial is testing in 10,000 patients with type 2 diabetes mellitus, elevated triglycerides, and low levels of HDL-C whether treatment with this SPPARMα agonist safely reduces residual cardiovascular risk. ? 2019 The Author(s).Atherogenic dyslipidemia; Diabetes; Inflammation; Pemafibrate (K-877); PROMINENT; Remnant cholesterol; Residual cardiovascular risk; Selective peroxisome proliferator-activated receptor alpha modulator; SPPARMalpha; Triglycerides; Visceral obesity[SDGs]SDG3high density lipoprotein cholesterol; peroxisome proliferator activated receptor alpha agonist; triacylglycerol; (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid; antilipemic agent; benzoxazole derivative; biological marker; butyric acid derivative; lipid; peroxisome proliferator activated receptor alpha; PPARA protein, human; atherogenesis; cardiometabolic risk; cardiovascular risk; conceptual framework; coronary artery atherosclerosis; disease association; disease exacerbation; drug efficacy; drug safety; dyslipidemia; high risk patient; human; lipoprotein metabolism; non insulin dependent diabetes mellitus; nonalcoholic fatty liver; population research; preclinical study; prevalence; Review; risk factor; risk reduction; treatment outcome; treatment planning; triacylglycerol blood level; animal; blood; cardiovascular disease; consensus; dyslipidemia; metabolism; molecularly targeted therapy; patient safety; risk assessment; signal transduction; Animals; Benzoxazoles; Biomarkers; Butyrates; Cardiovascular Diseases; Consensus; Dyslipidemias; Humans; Hypolipidemic Agents; Lipids; Molecular Targeted Therapy; Patient Safety; PPAR alpha; Risk Assessment; Risk Factors; Signal Transduction; Treatment Outcomereview10.1186/s12933-019-0864-7311641652-s2.0-85066822428